Search Icon
SideMenu

The Generics Industry Wants a Healthy America

Low-cost generics and biosimilars positively impact the health of American patients. Plus, over the past decade, widespread adoption has saved the U.S. healthcare system $3.1 trillion. But this success story is in jeopardy.

Learn More

2024 U.S. Generic & Biosimilar Medicines Savings Report

Generic and biosimilar medicines saved $445 billion in 2023. Representing 90 percent of prescriptions filled but only 13 percent of spending, generics and biosimilars are an integral part of the U.S. healthcare system. However, the sustainability of this industry remains fragile.

View Full Report

AAM White Paper: Hatch-Waxman Turns 40

“Since the introduction of this law, we have all seen incredible savings. But even as we celebrate the success of forty years of Hatch-Waxman, those savings, the increased patient access, and a model of generic adoption that leads the world, are at risk.” —David Gaugh, Interim President & CEO, AAM.

View Press Release

Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why?

Avalere analysis finds Part D prescription drug plans continue to increase patient copays for generics by moving them to higher tiers.

Read Blog

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers of generic and biosimilar medicines and combatting anti-competitive abuses by some brand drug companies who put profits before patients.
Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of generic and biosimilar medicines and to drive down the cost of developing new ones, expanding access to as many people as possible.
Learn More
We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable generic and biosimilar medicines.
Learn More

Policy

About AAM

The Biosimilars Council works to increase patient access to lifesaving, affordable biosimilar medicines.

The council – comprised of biosimilar manufacturers and stakeholders working to promote biosimilar products in the U.S. market – strives to create a positive regulatory, reimbursement, political and policy environment to assure biosimilars thrive, ultimately providing billions in savings to patients and the health care system.

Learn More

Recent Updates
  • Press Releases

Amphastar to Quadruple Domestic Manufacturing
  • Blog

Long-Term Effects of Medicare Price Negotiations on Drug Competition
  • Press Releases

Medicare Drug Price Negotiation has Chilling Effect on Generic and Biosimilar Medicines Development and Availability
  • Press Releases

Patent Thickets and Litigation Abuses Hinder all Biosimilars
  • Press Releases

Groups Join the Biosimilars Council and AAM Letter of Support for Interchangeability Legislation
  • Press Releases

Mark Ratner Joins AAM to Lead Government Relations
Load More

Generics are a proven prescription for a healthier society.

Generic and biosimilar medicines make it easier and more affordable for patients to live healthier lives.

Learn More

Conferences

Conference
  • October 27-
  • 29, 2025

GRx+Biosims 2025
Conference
  • February 23-
  • 25, 2026

Access! 2026

Stay Informed

Association for Accessible Medicines
601 New Jersey Ave NW, Suite 850
Washington DC 20001
JOIN

Advocacy

About Us

Events

Resources

Sign-up for Update

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Subscribe

© 2025 Association for Accessible Medicines (AAM), All Rights Reserved
Privacy Policy  |  Terms of Use  |  Contact

Stay Connected

For the latest updates, follow us on social media.

Facebook-f X-twitter Linkedin-in Youtube Instagram